atezolizumab + Vigil

**atezolizumab + Vigil** is a combination of two immunotherapies: - **Atezolizumab** is a monoclonal antibody checkpoint inhibitor targeting programmed death-ligand 1 (PD-L1); it blocks PD-L1 interactions to enhance T-cell mediated anti-tumor immunity. - **Vigil** (gemogenovatucel-T) is a personalized autologous tumor cell vaccine engineered to express granulocyte-macrophage colony-stimulating factor (GM-CSF) and decrease expression of furin and downstream TGF-β1/2, increasing tumor neoantigen expression and amplifying immune activation[2][3][5]. Vigil is designed to focus immune responses on tumor cells, while atezolizumab reduces tumor immune evasion[1][2][3]. This combination is primarily investigated in patients with relapsed/recurrent ovarian cancer and BRCA-wildtype status. Studies show encouraging safety and potential efficacy, particularly when Vigil is administered prior to atezolizumab[2][3].

Brand names

Tecentriq

Other names

gemogenovatucel-Tatezolizumab + gemogenovatucel-T